scispace - formally typeset
P

Pablo Tamayo

Researcher at University of California, San Diego

Publications -  185
Citations -  117545

Pablo Tamayo is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Gene. The author has an hindex of 72, co-authored 177 publications receiving 97318 citations. Previous affiliations of Pablo Tamayo include University of California, Berkeley & Harvard University.

Papers
More filters

A resampling-based method for class discovery and visualization of gene expression microarray data

TL;DR: A new methodology of class discovery and clustering validation tailored to the task of analyzing gene expression data is presented and in conjunction with resampling techniques, it provides for a method to represent the consensus across multiple runs of a clustering algorithm and to assess the stability of the discovered clusters.
Journal ArticleDOI

Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy

TL;DR: A comprehensive analysis of GPCR gene expression, copy number variation, and mutational signatures in 33 cancer types is presented and highlights the emerging role of G PCRs as part of oncocrine networks promoting tumor growth, dissemination, and immune evasion.
Journal ArticleDOI

Integrative radiogenomic profiling of squamous cell lung cancer

TL;DR: The development of a high-throughput platform for measuring radiation survival in vitro and its validation in comparison with conventional clonogenic radiation survival analysis is reported and pathways implicated in cell survival, genotoxic stress, detoxification, and innate and adaptive immunity are identified as key correlates of radiation sensitivity.
Journal ArticleDOI

An expanded universe of cancer targets.

William C. Hahn, +124 more
- 04 Mar 2021 - 
TL;DR: A framework is described for this expanded list of cancer targets, providing novel opportunities for clinical translation and indicating that the diversity of therapeutic targets engendered by non-oncogene dependencies is much larger than the list of recurrently mutated genes.